Together with her colleagues, EBPI researcher and head of the Cancer Registry
of Zurich and Zug PD Dr. Sabine Rohrmann was recently awarded funding by
the Swiss Cancer League to analyze nearly 35 years worth of data on outcomes
for residents of the Canton of Zurich diagnosed with a non-invasive type of breast
cancer. In situ breast cancer is a non-invasive form of breast cancer often detected through cantonal mammography screenings that have become more common in recent years. About 25% of women with an in situ breast cancer are later diagnosed with malignant invasive breast cancer. Dr. Rohrmann’s investigation will contribute to a better understanding of the epidemiology of in situ breast cancer. Specifically, the work aims to identify the risk of subsequent invasive breast cancer, which will provide clinicians and researchers with information about which treatments are associated with a lower risk of invasive breast cancer later in life.